Japanese and Mid-Sized European Biotech Licensings

Alliance activity over the last few years suggests that Japanese companies are more willing to take a chance on less proven, earlier-stage technology than mid-sized European companies.

This month, we compared licensing deals with public biotech partners struck by mid-sized European partners to those done by the top 15 Japanese pharmaceutical companies to highlight the differences in dealmaking styles of these highly regional players. We only used deals in which the licensee acquired rights only in its own region, leaving the biotech partner free to license the remainder of the worldwide marketing rights to a multinational.

As the chart below illustrates, it seems Japanese partners are more willing to take a chance on less-proven, earlier-stage technology...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Global Vision

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.